查加斯病治疗疗效标志物:儿童用尼福蒂莫克斯III期研究的经验
Ulrike Grossmann1, Maria-Luisa Rodriguez2
1Research and Development Pharmaceuticals, Bayer AG, Berlin, Germany.
Frontiers in parasitology
|January 16, 2025
概括
由于持续的血清阳性,衡量夏加斯病治疗成功是很困难的. 这项研究探讨了血清分泌作为一种替代标志物,用于儿童的抗松体药物疗效,以及既定的治愈标准.
科学领域:
- 寄生虫学的寄生虫学
- 传染性疾病 传染性疾病
- 临床药理学 临床药理学
背景情况:
- 对查加斯病,特别是慢性病例的抗松体治疗疗法的有效性进行评估是具有挑战性的.
- 在成功治疗后持续的血清阳性复杂化了治疗方法的确定.
- 目前行业缺乏关于确定药物有效性的指导.
研究的目的:
- 通过使用酶相关的免疫吸收试验来评估血清减少,作为抗松索治疗疗效的替代标记.
- 介绍一项使用nifurtimox治疗查加斯病的儿科III期试验的经验.
- 与美国FDA等监管机构讨论代孕疗效参数.
主要方法:
- 利用了通过两种酶链免疫吸收剂测定来测量的血清减少.
- 作为已确定的治愈标准,与血清转换为负的组合替代标记物.
- 进行了儿童临床试验III期,使用nifurtimox.
主要成果:
- 血清递减被探索为治疗疗效的替代参数.
- 介绍了使用nifurtimox的儿科试验的经验.
- 该研究讨论了查加斯病药物试验中替代标记物的验证.
结论:
- 需要经过验证的代用标记物来有效监测抗松体治疗疗效.
- 血清减少可以作为一个有价值的替代标记在查加斯病的临床试验.
- 这种观点为确定查加斯病治疗药物的有效性提供了洞察力.
相关概念视频
Clinical Trials: Overview
Clinical development focuses on how the drug will interact with the human body and encompasses four key phases of clinical trials, each serving a specific purpose in assessing the safety and effectiveness of new drugs. These phases overlap and build upon one another. Phase I involves a small group of healthy volunteers (typically 20-80 individuals) or, in cases where significant toxicity is expected, patients with the targeted disease, such as cancer or AIDS. The volunteers are tested for...
Drug Dosing: Infants and Children
Pediatric patient dosages diverge from adults due to disparities in body surface area, total body water, and extracellular fluid per kilogram of body weight. The dosing regimen considers the variations in pharmacokinetics and pharmacology across distinct age groups, encompassing preterm newborns, infants, young children, older children, and adolescents. Calculation of pediatric patient doses is predicated on determining body surface area, which exhibits a superior correlation with the child's...
Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption
Understanding the physiological differences in the pediatric population is crucial for effective pharmacotherapy. Neonates, infants, and children exhibit significant variations in gastric pH, gastric emptying time, intestinal transit time, and biliary function. These variations profoundly affect oral drug absorption, necessitating a nuanced approach to pediatric dosing.Neonates present with a unique physiological profile, having a gastric pH greater than 4 and faster and more irregular gastric...
Pharmacokinetics in Pediatric Patients: Drug Distribution
Drug distribution in the pediatric population exhibits unique challenges and considerations due to the physiological differences between children, particularly neonates and infants, and adults. A crucial aspect of pediatric pharmacology is understanding how these differences impact the pharmacokinetics of various drugs, necessitating age-specific dosing strategies to ensure efficacy and safety.Neonates and infants have a higher total body water content, ~75%–90% of their body weight, compared...
Pharmacokinetics in Pediatric Patients: Drug Metabolism
In pediatric care, understanding the nuances of hepatic drug metabolism is crucial, as it significantly differs from that of adults. This divergence is primarily due to the developmental stage of drug-metabolizing enzymes, which affects how medications are processed in the body. In neonates, for instance, the activity of Phase I enzymes—critical for the initial breakdown of drugs—is markedly reduced, functioning at just 20–40% of the levels seen in adults. This reduction poses a challenge in...
Pharmacokinetics in Pediatric Patients: Drug Excretion
In pediatric medicine, understanding the renal function and drug elimination nuances is crucial for administering safe and effective treatments. Newborns, in particular, display markedly slower renal functions than adults, profoundly affecting how drugs are cleared from their bodies. This slower drug clearance requires clinicians to extend the dosing intervals for many medications to prevent drug accumulation and toxicity while ensuring therapeutic efficacy.One key area where these adjustments...


